Dexcom (DXCM): financials, SEC filings and peers

Dexcom (DXCM) is a health care equipment company in the Health Care sector of the S&P 500, headquartered in San Diego, California.

It was founded in 1999 and joined the S&P 500 on May 12, 2020.

Its fiscal year ends in December, and its shares trade on the Nasdaq.

In its SEC filings it is classified as “Surgical & Medical Instruments & Apparatus”.

Dexcom at a glance

Revenue (12 months): $5.0B
Revenue growth: +15.5%
Operating margin: 22.9%
Net income (12 months): $1000M
Free cash flow (12 months): $1.4B
Cash: $1.1B
Debt: —
Diluted EPS (12 months): $2.52

Twelve months to June 30, 2026, from the 10-Q filed July 30, 2026.

Latest twelve months

Over the twelve months to June 30, 2026, Dexcom reported revenue of $5.0 billion, up 15.5% from a year earlier.

Its operating margin was 22.9%, up 6.9 percentage points from a year earlier: for every $100 of sales, about $23 was left as operating profit.

Net income was $1000 million (20.1% of revenue), 74.9% higher than a year earlier.

Operating cash flow was $1.7 billion and capital spending $344 million, leaving free cash flow of $1.4 billion (28.3% of revenue).

At the end of the period it held $1.1 billion in cash and not reported in debt, a net cash position of $1.1 billion.

The diluted share count fell 4.4% in a year, typically the result of buybacks.

Five-year trend

Revenue went from $1.9 billion in fiscal 2020 to $4.7 billion in fiscal 2025, about 19.3% a year.
Revenue has grown for 5 fiscal years in a row.
Operating margin widened from 15.5% to 19.6% over the same years.
Free cash flow was positive in each of the last 6 fiscal years.

Fiscal year	2021	2022	2023	2024	2025
Revenue	$2.4B	$2.9B	$3.6B	$4.0B	$4.7B
Revenue growth	27.1%	18.8%	24.5%	11.3%	15.6%
Operating margin	10.9%	13.4%	16.5%	14.9%	19.6%
Net income	$217M	$341M	$542M	$576M	$836M
Free cash flow	$53M	$305M	$512M	$631M	$1.1B
Diluted EPS	$0.53	$0.82	$1.30	$1.42	$2.09

Fiscal years as reported in Dexcom’s 10-K filings. Free cash flow is operating cash flow minus capital spending.

Recent SEC filings

8-K filed September 14, 2026 — Executive or director change; Regulation FD disclosure
8-K filed September 10, 2026 — Executive or director change; Regulation FD disclosure
10-Q filed July 30, 2026 — quarterly report
8-K filed July 30, 2026 — Earnings results
8-K filed May 28, 2026 — Shareholder vote results
8-K filed May 15, 2026 — Regulation FD disclosure; Other event
10-Q filed April 30, 2026 — quarterly report
8-K filed April 30, 2026 — Earnings results

All Dexcom filings on SEC EDGAR

Companies like Dexcom

Other S&P 500 companies in Health Care Equipment:

More from Health Care

All 60 Health Care companies →

Questions about Dexcom

Is Dexcom's revenue growing?

Yes. Revenue for the twelve months to June 30, 2026 was $5.0 billion, up 15.5% from a year earlier, according to its SEC filings.

Is Dexcom profitable?

Yes. It earned $1000 million in net income over the twelve months to June 30, 2026, a net margin of 20.1%.

When did Dexcom last file financial results?

Its latest quarterly report (10-Q) was filed with the SEC on July 30, 2026.

Which companies are similar to Dexcom?

In the S&P 500, Dexcom is grouped in Health Care Equipment within the Health Care sector. Abbott Laboratories (ABT), Baxter International (BAX), Becton Dickinson (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW) are in the same group.

Understand the numbers

Source: Dexcom’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.